See the DrugPatentWatch profile for entresto
Generic Entresto has not yet been released. The current patent protection for Entresto is set to expire in 2025 [1].
Will Entresto Go Off-Patent Soon?
Entresto's market exclusivity is expected to end in 2025, at which point generic versions could become available [1].
What Does Entresto Treat?
Entresto is a medication used to treat heart failure with reduced ejection fraction [2]. It works by blocking the effects of certain hormones that can worsen heart failure [2].
How Does Entresto Compare to Other Heart Failure Treatments?
Entresto has demonstrated significant benefits in reducing cardiovascular death and hospitalization for heart failure compared to ACE inhibitors in clinical trials [2].
Who Manufactures Entresto?
Novartis is the pharmaceutical company that developed and manufactures Entresto [3].
When Did Novartis's Patent for Entresto Become Effective?
Novartis obtained U.S. Patent No. 8,940,772 for Entresto on January 27, 2015 [1].
Are There Any Biosimilars or Generics in Development for Entresto?
Information regarding specific generic or biosimilar development for Entresto is not publicly available at this time. However, once patent exclusivity expires, generic manufacturers can apply for approval to market their versions of the drug [1].
What Is the Typical Timeline for Generic Drug Approval After Patent Expiry?
After a drug's patent expires, generic manufacturers can submit an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA). The FDA then reviews the application to ensure the generic drug is equivalent to the brand-name product in dosage, safety, strength, route of administration, quality, performance, and intended use. The approval process timeline can vary.
Sources:
[1] DrugPatentWatch.com
[2] Novartis
[3] U.S. Food & Drug Administration